GO
Loading...

Amgen Inc

More

  • Early Glance: Biotechnology companies Wednesday, 27 Aug 2014 | 10:17 AM ET

    Amgen Inc. rose$. 09 or. 1 percent, to $137.36. Biogen Idec fell $3.75 or 1.1 percent, to $339.24. Celgene Corp. fell$. 64 or. 7 percent, to $95.02.

  • Final Glance: Biotechnology companies Tuesday, 26 Aug 2014 | 6:05 PM ET

    Amgen Inc. rose $2.48 or 1.8 percent, to $137.27. Biogen Idec rose$. 29 or. 1 percent, to $342.99. Celgene Corp. rose $2.26 or 2.4 percent, to $95.66.

  • Midday Glance: Biotechnology companies Tuesday, 26 Aug 2014 | 1:31 PM ET

    Amgen Inc. rose $2.37 or 1.8 percent, to $137.16. Biogen Idec fell $1.54 or. 4 percent, to $341.16. Celgene Corp. rose $2.04 or 2.2 percent, to $95.44.

  • Aug 26- Pfizer Inc said Tuesday it will test its Xalkori lung cancer drug with Merck& Co's experimental immunotherapy pembrolizumab, in hopes the combination will improve the outcomes for patients taking the approved Pfizer therapy. The largest U.S. drugmakers said the combination study will begin in 2015 and be conducted by Pfizer.

  • Early Glance: Biotechnology companies Tuesday, 26 Aug 2014 | 11:11 AM ET

    Amgen Inc. rose$. 91 or. 7 percent, to $135.70. Biogen Idec fell $1.34 or. 4 percent, to $341.36. Celgene Corp. rose $1.02 or 1.1 percent, to $94.42.

  • Aug 26- Pfizer Inc said Tuesday it will test its Xalkori lung cancer drug with Merck& Co's experimental immunotherapy pembrolizumab, in the hopes the combination will improve the outcomes for patients taking the approved Pfizer therapy. The largest U.S. drugmakers said the combination study will begin in 2015 and be conducted by Pfizer.

  • Final Glance: Biotechnology companies Monday, 25 Aug 2014 | 6:24 PM ET

    Amgen Inc. rose $1.97 or 1.5 percent, to $134.79. Biogen Idec rose $2.73 or. 8 percent, to $342.70. Celgene Corp. rose $1.78 or 1.9 percent, to $93.40.

  • Early Glance: Biotechnology companies Monday, 25 Aug 2014 | 10:37 AM ET

    Amgen Inc. rose $1.75 or 1.3 percent, to $134.57. Biogen Idec rose $4.39 or 1.3 percent, to $344.36. Celgene Corp. rose $1.61 or 1.8 percent, to $93.23.

  • LOS ANGELES, Aug 25- U.S. regulators are likely to approve Merck& Co's highly anticipated immuno-oncology drug, pembrolizumab, as a treatment for melanoma well ahead of a late October deadline, according to three sources familiar with the situation.

  • Final Glance: Biotechnology companies Friday, 22 Aug 2014 | 6:02 PM ET

    Amgen Inc. rose$. 29 or. 2 percent, to $132.82. Biogen Idec rose $1.32 or. 4 percent, to $339.97. Celgene Corp. fell$. 04 or percent, to $91.62.

  • Midday Glance: Biotechnology companies Friday, 22 Aug 2014 | 1:21 PM ET

    Amgen Inc. rose$. 73 or. 6 percent, to $133.26. Biogen Idec rose $2.22 or. 7 percent, to $340.87. Celgene Corp. rose$. 09 or. 1 percent, to $91.75.

  • Final Glance: Biotechnology companies Thursday, 21 Aug 2014 | 6:08 PM ET

    Amgen Inc. fell$. 15 or. 1 percent, to $132.53. Biogen Idec fell $3.93 or 1.1 percent, to $338.65. Celgene Corp. fell$. 34 or. 4 percent, to $91.66.

  • Midday Glance: Biotechnology companies Thursday, 21 Aug 2014 | 1:22 PM ET

    Amgen Inc. rose$. 03 or percent, to $132.71. Biogen Idec fell $2.14 or. 6 percent, to $340.45. Celgene Corp. rose$. 02 or percent, to $92.02.

  • Aug 21- An experimental new psoriasis treatment from Eli Lilly and Co proved superior to Amgen Inc's blockbuster Enbrel, drawing it closer to a potential marketing battle with new products being developed by Amgen and Novartis AG.

  • Lilly psoriasis drug fares well in late-stage test Thursday, 21 Aug 2014 | 8:55 AM ET

    INDIANAPOLIS— Drugmaker Eli Lilly and Co. said its potential psoriasis treatment fared better than both a fake drug and a competitor's product during late-stage testing on patients with the most common form of the skin disease.

  • Final Glance: Biotechnology companies Wednesday, 20 Aug 2014 | 6:02 PM ET

    Amgen Inc. fell$. 34 or. 3 percent, to $132.68. Biogen Idec fell $3.26 or. 9 percent, to $342.58. Celgene Corp. rose$. 64 or. 7 percent, to $92.00.

  • Midday Glance: Biotechnology companies Wednesday, 20 Aug 2014 | 1:49 PM ET

    Amgen Inc. fell$. 35 or. 3 percent, to $132.67. Biogen Idec fell $2.66 or. 8 percent, to $343.18. Celgene Corp. rose $1.38 or 1.5 percent, to $92.74.

  • Early Glance: Biotechnology companies Wednesday, 20 Aug 2014 | 12:21 PM ET

    Amgen Inc. fell$. 61 or. 5 percent, to $132.41. Biogen Idec fell $1.68 or. 5 percent, to $344.16. Celgene Corp. rose $1.47 or 1.6 percent, to $92.83.

  • Final Glance: Biotechnology companies Tuesday, 19 Aug 2014 | 6:08 PM ET

    Amgen Inc. fell$. 20 or. 2 percent, to $133.02. Biogen Idec rose $1.24 or. 4 percent, to $345.84. Celgene Corp. rose$. 05 or. 1 percent, to $91.36.

  • Midday Glance: Biotechnology companies Tuesday, 19 Aug 2014 | 4:03 PM ET

    Amgen Inc. fell $1.29 or 1.0 percent, to $131.93. Biogen Idec fell$. 31 or. 1 percent, to $344.29. Celgene Corp. rose$. 10 or. 1 percent, to $91.41.